Tonix Pharmaceuticals (TNXP) Expected to Announce Earnings on Tuesday

Tonix Pharmaceuticals (NASDAQ:TNXP) will likely be issuing its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect the company to announce earnings of ($3.16) per share and revenue of $2.9670 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 20, 2026 at 4:00 PM ET.

Tonix Pharmaceuticals Trading Up 3.6%

Shares of NASDAQ TNXP opened at $13.94 on Tuesday. The company has a market capitalization of $178.29 million, a price-to-earnings ratio of -0.69 and a beta of 1.88. Tonix Pharmaceuticals has a twelve month low of $12.35 and a twelve month high of $69.97. The business has a 50 day simple moving average of $15.82 and a 200-day simple moving average of $19.42.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Tonix Pharmaceuticals by 238.1% in the third quarter. Vanguard Group Inc. now owns 556,957 shares of the company’s stock worth $13,456,000 after buying an additional 392,225 shares during the period. Geode Capital Management LLC grew its position in shares of Tonix Pharmaceuticals by 35.3% during the fourth quarter. Geode Capital Management LLC now owns 271,904 shares of the company’s stock worth $4,248,000 after acquiring an additional 70,970 shares during the last quarter. State Street Corp increased its holdings in shares of Tonix Pharmaceuticals by 25.8% in the 4th quarter. State Street Corp now owns 191,855 shares of the company’s stock worth $2,997,000 after acquiring an additional 39,311 shares during the period. Balyasny Asset Management L.P. acquired a new stake in shares of Tonix Pharmaceuticals in the 4th quarter worth about $2,895,000. Finally, Nuveen LLC lifted its position in Tonix Pharmaceuticals by 507.7% in the 4th quarter. Nuveen LLC now owns 93,402 shares of the company’s stock valued at $1,459,000 after purchasing an additional 78,033 shares during the last quarter. Institutional investors and hedge funds own 82.26% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on TNXP. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a report on Wednesday, January 21st. Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, January 17th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $70.00.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.